60 Degrees Pharmaceuticals announced a private placement offering of 574,713 shares and warrants at $1.74 each, expected to raise about $1 million before fees. The offering includes series A and B warrants exercisable at $1.49 per share, with expiration terms of five years and two years respectively. Proceeds will support working capital and general corporate purposes. The company specializes in medicines for vector-borne diseases and has FDA-approved malaria prevention drug ARAKODA® available in the US and Australia.
PHINIA's CEO Ericson Brady D sold 27,860 shares in two transactions, reducing his holdings to 330,497 shares. The company, a key automotive parts supplier, has a Price-to-Earnings ratio of 19.32 and an earnings yield of 5.21%, indicating steady inves...
Rezolve AI reported a massive 1,970% revenue increase to $130.8 million in H1 2026 but saw its net loss widen to $139.5 million. Roth Capital lowered the price target from $9.50 to $6.50 while keeping a Buy rating, reflecting confidence despite losse...
Sprinklr reported Q2 2027 earnings per share of $0.11, beating analyst estimates by 10%, continuing a four-quarter streak of profit outperformance. Although total revenue of $213.74 million slightly missed the $214.45 million estimate, it still grew ...
Argan, Inc. is set to release its Q3 earnings with analysts expecting an EPS of $2.64 and revenue of $300.53 million. The company recently exceeded earnings and revenue estimates by 42.7% and 15.2%, driven by strong demand in power services. With a $...
Public Storage reported Q2 2026 core Funds From Operations (FFO) per share of $4.17, slightly missing analyst estimates by 1.9% due to a 2.2% drop in same-store net operating income. Despite this, the company completed a $1.2 billion acquisition of P...
